Roughly one in 14 people with lower-risk myelodysplastic syndromes (LR-MDS) have an infection in the first year after ...

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

Myelodysplastic syndromes (MDS) comprise the most common malignant blood disorder. MDS are increasing in frequency owing to an ageing population and increased awareness of these diseases.

Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients ...

A diagnosis of myelodysplastic syndrome is made through the examination of the peripheral blood (circulating blood in veins and arteries) and the bone marrow. Certain genetic abnormalities in cells ...

These tips can help you better manage MDS fatigue. Myelodysplastic syndromes (MDS) is a type of cancer that shows up as a group of conditions affecting your bone marrow and blood. “Myelo ...

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a ...

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

Myelodysplastic syndromes (MDS) is a group of blood cancers. Red and white blood cells and platelets start as immature blood stem cells. In MDS, your blood stem cells do not mature into full ...